176 related articles for article (PubMed ID: 8319490)
21. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
22. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
[TBL] [Abstract][Full Text] [Related]
24. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
Noble S; Goa KL
BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
[TBL] [Abstract][Full Text] [Related]
25. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.
Howes J; Novack GD
J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541
[TBL] [Abstract][Full Text] [Related]
26. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
Oner V; Türkcü FM; Taş M; Alakuş MF; Işcan Y
Jpn J Ophthalmol; 2012 Jul; 56(4):312-8. PubMed ID: 22622345
[TBL] [Abstract][Full Text] [Related]
27. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
Lu E; Fujimoto LT; Vejabul PA; Jew RL
Optometry; 2011 Jul; 82(7):413-20. PubMed ID: 21543264
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
White EM; Macy JI; Bateman KM; Comstock TL
Curr Med Res Opin; 2008 Jan; 24(1):287-96. PubMed ID: 18062846
[TBL] [Abstract][Full Text] [Related]
29. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
Comstock TL; Sheppard JD
Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
[TBL] [Abstract][Full Text] [Related]
30. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
31. Treatment of ocular inflammatory conditions with loteprednol etabonate.
Pavesio CE; Decory HH
Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.
Chen M; Gong L; Sun X; Gu Y; He X; Qu J; Wang L; Zhang M; Zhong X
Curr Med Res Opin; 2012 Mar; 28(3):385-94. PubMed ID: 22256909
[TBL] [Abstract][Full Text] [Related]
33. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
Rajpal RK; Fong R; Comstock TL
Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
[TBL] [Abstract][Full Text] [Related]
34. Suprofen treatment of contact lens-associated giant papillary conjunctivitis.
Wood TS; Stewart RH; Bowman RW; McCulley JP; Reaves TA
Ophthalmology; 1988 Jun; 95(6):822-6. PubMed ID: 3211485
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
36. Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.
Novack GD
Clin Ther; 2002 Sep; 24(9):1477-8; author reply 1478-80. PubMed ID: 12380639
[No Abstract] [Full Text] [Related]
37. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
Howes JF; Baru H; Vered M; Neumann R
J Ocul Pharmacol; 1994; 10(1):289-93. PubMed ID: 8207332
[TBL] [Abstract][Full Text] [Related]
38. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
[TBL] [Abstract][Full Text] [Related]
39. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
